Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy.

A total of 65 (63% (41/65) females) moderate-to-severe, active TAO patients aged 50 ± 13 (25-74) years received 6-weekly (n = 22) or 12-weekly (n = 43) IVMP. Sex, age, smoking status, and Graves' disease status were comparable in the two groups (all > 0.05). CAS at week 6 ( = 0.0279), 12 ( = 0.00228), and 52 ( = 0.0228) were lower at each time for the 12-weekly group. Exophthalmos improved more at week 6 ( = 0.0453) and 12 ( = 0.0347) in the 12-weekly group. The improvement of diplopia, MRD1, MRD2, and EOMy were comparable between the two groups. More patients in the 6-weekly group ( = 0.00169) required additional treatments including IVMP+/-ORT. Patients in the 6-weekly group who did not require additional treatment had a lower presenting CAS ( = 0.0193) than those who required additional treatment. The total numbers of adverse events were comparable between the two groups.